This publication does not publish anonymous letters to the editor. Please fill out all of the information below so that our editorial staff may contact you with any questions and confirm your ...
Trametinib, a mitogen-activated protein kinase (MEK) inhibitor, reduces mortality and morbidity in children with severe hypertrophic cardiomyopathy (HCM) caused by pathogenic variants in the RAS/MAPK ...